Tommy Leggett

Tommy brings more than two decades of experience in financial operations and has led and obtained financing for dozens of life science companies. Before joining Affinia Therapeutics, Tommy was CFO at Black Diamond Therapeutics, where he was critical in leading the company’s $85 million Series C financing and $231 million initial public offerings (IPO), while he also oversaw Black Diamond’s financial strategy, investor relations, corporate communications, financial operations, financial planning & analysis, and portfolio strategy and analytics. Before joining Black Diamond, Mr. Leggett served as CFO at Axcella Health, where he helped raise $156 million across three financings, including an IPO. Before joining the biotech industry, Tommy spent over a decade as an investment banker for the healthcare groups at J.P. Morgan Securities, Lazard Frères & Company, and UBS Securities. He has also served on the board of directors of Clover Biopharmaceuticals, Ltd. since September 2021 and on the board of directors of Research Alliance Corp. II since February 2021. He received a B.A. in economics from Columbia University and an M.B.A. in finance from the Wharton School at the University of Pennsylvania.